IMMCO DIAGNOSTICS LAUNCHES NEW PATENTED TESTS FOR DIAGNOSIS OF CHRONIC RHINOSINUSITIS
BUFFALO, New York – June 17, 2013 -- Immco Diagnostics Inc. (Immco), has received New York State Department of Health (NYSDOH) approval of the new patented laboratory tests for diagnosis of fungal-mediated Chronic Rhinosinusitis (CRS). CRS is a common and often debilitating form of sinusitis marked by prolonged or recurring inflammation of the nose and paranasal sinus. Diagnosis and treatment can be challenging and many sufferers improperly self-diagnose with nasal allergies and ineffectively self-treat their symptoms. Proper treatment for non-allergic fungal-mediated CRS differs significantly from treatment for allergies or other chronic inflammation of the sinus.
Immco in partnership with the Mayo Clinic has developed next generation diagnostics tests for fungal-mediated CRS. Testing is performed at the Immco reference laboratory, located on the Buffalo Niagara Medical Campus. Specimens are collected throughout the United States by ENTs (ear, nose and throat specialists) and sent to Immco.
“This technology represents an important advance in the proper diagnosis of fungal-mediated CRS. We hope that innovative, simplified diagnostics lead to improved quality of life for CRS sufferers,” said Bill Maggio, President and CEO, of Immco Diagnostics. With better diagnostic options, patients properly diagnosed with fungal-mediated CRS may benefit from a course of anti-fungal therapy. Removal of the fungal antigens will often cause the immunological inflammatory response to subside.
About Immco Diagnostics:
Immco incorporates innovative medical devices, laboratory testing expertise and pioneering research into comprehensive solutions for autoimmune disease diagnosis. Immco develops and distributes autoimmune disease test kits and reagents to labs worldwide. The company offers reference laboratory testing to the US healthcare market and well as contract research services supporting clinical trials for pharmaceutical and biotech clients.
Source: Immco Diagnostics, Inc.
William J. Maggio, CEO
Tel. +176 691 0091